Classic preventive vaccines are designed to mimic the effectsof natural exposure to microbes. They provide a high level oflong-lasting protection against infection in the vast majorityof recipients and serve as free-standing preventive measures.Although a classic preventive vaccine remains the ultimate goalof efforts to develop a vaccine for protection against the humanimmunodeficiency virus (HIV), the enormous genetic diversityand other unique features of the HIV envelope protein have thusfar thwarted attempts to identify an effective candidate. However,we have learned from studies of HIV pathogenesis in humans andfrom animal models that a vaccine . . . [Full Text of this Article]
Obstacles to Vaccine Development
Early Focus on Monomeric Envelope Proteins
T-Cell Immunity in the Control of HIV Infection
T-Cell Vaccines
Complicating Factors
Research Issues
Conclusions
Source Information
From the Division of AIDS (M.I.J.) and the Office of the Director (A.S.F.), National Institute of Allergy and Infectious Diseases, Bethesda, MD.
Address reprint requests to Dr. Fauci at the National Institute of Allergy and Infectious Diseases, 31 Center Dr., MSC 2520, Bldg. 31, Rm. 7A03, Bethesda, MD 20892, or at afauci@niaid.nih.gov.
This article has been cited by other articles:
Taylor, B. S., Sobieszczyk, M. E., McCutchan, F. E., Hammer, S. M.
(2008). The Challenge of HIV-1 Subtype Diversity. NEJM
358: 1590-1602
[Full Text]
Balamurugan, A., Lewis, M. J., Kitchen, C. M. R., Robertson, M. N., Shiver, J. W., Daar, E. S., Pitt, J., Ali, A., Ng, H. L., Currier, J. S., Yang, O. O.
(2008). Primary Human Immunodeficiency Virus Type 1 (HIV-1) Infection during HIV-1 Gag Vaccination. J. Virol.
82: 2784-2791
[Abstract][Full Text]
Harari, A., Bart, P.-A., Stohr, W., Tapia, G., Garcia, M., Medjitna-Rais, E., Burnet, S., Cellerai, C., Erlwein, O., Barber, T., Moog, C., Liljestrom, P., Wagner, R., Wolf, H., Kraehenbuhl, J.-P., Esteban, M., Heeney, J., Frachette, M.-J., Tartaglia, J., McCormack, S., Babiker, A., Weber, J., Pantaleo, G.
(2008). An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med.
205: 63-77
[Abstract][Full Text]
Steinbrook, R.
(2007). One Step Forward, Two Steps Back -- Will There Ever Be an AIDS Vaccine?. NEJM
357: 2653-2655
[Full Text]
Butler, N. S., Dandekar, A. A., Perlman, S.
(2007). Antiviral Antibodies Are Necessary To Prevent Cytotoxic T-Lymphocyte Escape in Mice Infected with a Coronavirus. J. Virol.
81: 13291-13298
[Abstract][Full Text]
Peut, V., Kent, S. J.
(2007). Utility of Human Immunodeficiency Virus Type 1 Envelope as a T-Cell Immunogen. J. Virol.
81: 13125-13134
[Abstract][Full Text]
Tonks, A.
(2007). Quest for the AIDS vaccine. BMJ
334: 1346-1348
[Full Text]